Suppr超能文献

抗药性疣的接触免疫疗法。

Contact immunotherapy of resistant warts.

作者信息

Naylor M F, Neldner K H, Yarbrough G K, Rosio T J, Iriondo M, Yeary J

机构信息

Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock 79430.

出版信息

J Am Acad Dermatol. 1988 Oct;19(4):679-83. doi: 10.1016/s0190-9622(88)70222-4.

Abstract

Contact immunotherapy has been proved effective in the treatment of resistant warts. This report chronicles our experience with a new contact immunotherapy agent, diphenylcyclopropenone. We have achieved a cure rate of 62% in 45 patients with resistant warts of all types who came to our general dermatology clinic. Cure rates may be lower in patients who have experienced multiple treatment failures. The majority of cures were obtained within 3 to 4 months. Although it appears somewhat less effective than published reports of dinitrochlorobenzene contact immunotherapy, diphenylcyclopropenone contact immunotherapy is an effective treatment for resistant warts and avoids any potential problems from mutagenicity.

摘要

接触免疫疗法已被证明在治疗顽固性疣方面有效。本报告记录了我们使用一种新型接触免疫疗法药物二苯基环丙烯酮的经验。在来到我们普通皮肤科诊所的45例各种类型的顽固性疣患者中,我们取得了62%的治愈率。经历过多次治疗失败的患者治愈率可能较低。大多数治愈情况在3至4个月内实现。尽管二苯基环丙烯酮接触免疫疗法似乎比二硝基氯苯接触免疫疗法的已发表报告效果稍差,但它是治疗顽固性疣的一种有效方法,并且避免了任何潜在的致突变问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验